NVIDIA (NASDAQ:NVDA): Why its a Strong and Undervalued Buy
07 Mar

NVIDIA (NASDAQ:NVDA): Why its a Strong and Undervalued Buy

NVIDIA Corporation (NASDAQ:NVDA) has experienced tremendous growth, with its net income surging 144.89% year-over-year (YoY), driven by high demand for AI and data center GPUs. Despite this, NVDA stock has declined over 20% year-to-date (YTD), entering a bear market. However, this presents an opportunity for long-term investors as major tech…
Read Full
Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation
06 Mar

Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation

Plus Therapeutics Gains with FDA Orphan Drug Designation Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation, Plus Therapeutics a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics, has seen its stock skyrocket by +311.43%. This impressive surge follows the U.S. Food and Drug Administration's (FDA) decision to grant Orphan…
Read Full
Like Us
Follow Us
Subscribe Us
Follow Us
×